Bilcare Ltd
NSE: BI BSE: 526853Pharma
Incorporated in 1987, Bilcare Ltd. is engaged in the business of Pharmaceutical Packaging, Global Clinical Services, R&D services and Anti Counterfeit Technology (nCid).
₹62.1
52W: ₹50 — ₹116
PE 13.6 · Book ₹180 · -66% vs bookMarket Cap₹146 Cr
Stock P/E13.6Price to Earnings
ROCE1.58%Return on Capital
ROE0.51%Return on Equity
Div. Yield0%Face Value ₹10
Strengths
- +Company is almost debt free.
- +Stock is trading at 0.35 times its book value
- +Debtor days have improved from 143 to 82.3 days.
Weaknesses
- −Though the company is reporting repeated profits, it is not paying out dividend
- −The company has delivered a poor sales growth of -41.0% over past five years.
- −Promoter holding is low: 30.0%
- −Company has a low return on equity of -1.65% over last 3 years.
- −Contingent liabilities of Rs.714 Cr.
- −Earnings include an other income of Rs.22.1 Cr.
- −Working capital days have increased from 675 days to 1,530 days
Shareholding Pattern
Promoters30.01%
FIIs0.04%
DIIs0%
Public69.95%
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 30.01% | 30.01% | 30.01% | 30.01% | 30.01% | 30.01% | 30.01% | 30.01% |
| FIIs | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 69.95% | 69.95% | 69.95% | 69.95% | 69.95% | 69.94%▼0.0 | 69.95%▲0.0 | 69.95% |
Financial Statements
| Metric | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4.59 | 5.06 | 4.29 | 4.87 | 2.76 | 3.36 | 4.13 | 2.07 | 1.85 | 1.73 |
| Expenses | 6.64 | 6.28 | 8.68 | 5.72 | 5.49 | 3.88 | 5.7 | 3.48 | 3.21 | 3.47 |
| Operating Profit | -2.05 | -1.22 | -4.39 | -0.85 | -2.73 | -0.52 | -1.57 | -1.41 | -1.36 | -1.74 |
| OPM % | -44.66% | -24.11% | -102.33% | -17.45% | -98.91% | -15.48% | -38.01% | -68.12% | -73.51% | -100.58% |
| Net Profit | -4.04 | -1.55 | -2.49 | 1.4 | -2.57 | 1.81 | 3.36 | 3.59 | 1.04 | 2.71 |
| EPS ₹ | -1.72 | -0.66 | -1.06 | 0.59 | -1.09 | 0.77 | 1.43 | 1.52 | 0.44 | 1.15 |
AI Insights
Revenue Trend
TTM revenue at ₹10Cr, down 33.3% YoY. OPM at -62%.
Debt Position
Borrowings at ₹12Cr. Debt-to-equity ratio: 0.03x. Healthy balance sheet.
Institutional Flow
DIIs: 0% (+0.00pp change). FIIs: 0.04% (+0.00pp change). Promoters hold 30.01%.
Margin & Efficiency
ROCE improving from 0% (Mar 2014) to 2% (Mar 2025). Working capital days: 1530.
Valuation
PE 13.6x with 1.58% ROCE. Price is -66% above book value of ₹180. Dividend yield: 0%.
Recent Announcements
- Non-Applicability Of SEBI Circular No. SEBI/HO/DDHS/DDHS-RACPOD1/P/ CIR/2023/172 Dated October 19, 2023 29 Apr - Bilcare confirms it is not a Large Corporate under SEBI debt fundraising circular.
- Announcement under Regulation 30 (LODR)-Change in Directorate 25 Apr - Adv. Ashwini Hasabnis appointed additional independent director from 25 Apr 2026; committees reconstituted.
- Announcement under Regulation 30 (LODR)-Cessation 25 Apr - Madhuri Vaidya’s term ends 26 Apr 2026; Ashwini Hasabnis appointed independent director, committees reconstituted.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 16 Apr - Submitted Regulation 74(5) certificate for quarter ended 31 March 2026.
- Update On Voluntary Liquidation Of Wholly Owned Subsidiary - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015, 30 Mar - Converted 12,90,000 warrants into shares; redeemed 31,50,000 prefs (₹3.15cr); Bilcare GCS liquidation completed.
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Financial Year 2023 from bse